‘Egregious’ Ustekinumab Price Jump Shows Need for IRA
A US government report showed how a Medicare policy change made the drug ustekinumab (Stelara) for autoimmune diseases much more expensive, a finding that experts say illustrates the need for reforms created by the Inflation Reduction Act of 2022 (IRA). The topline findings of an August report from the Department of Health and Human Services …
Read More
0
